Demographic background of participants at baseline completing CQR at both timepoints.
| Characteristics | Participants Completing CQR Twice, Total | Participants Taking Stable Antirheumatic Therapy Completing CQR Twice, Subgroup | Participants Undergoing Treatment Change and Completing CQR Twice, Subgroup |
|---|---|---|---|
| Patients, n | 78 | 66 | 12 |
| Sex, male/female (female %) | 18/60 (76.9) | 15/51 (77.3) | 3/9 (75.0) |
| Age, yrs, mean ± SD | 58.9 ± 11.9 | 58.9 ± 11.7 | 59.1 ± 13.7 |
| Conventional DMARD therapies, n | 56 | 47 | 9 |
| MTX | 41 | 34 | 7 |
| SSZ | 5 | 4 | 1 |
| LEF | 8 | 8 | — |
| HCQ | 1 | — | 1 |
| AZA | 1 | 1 | — |
| Biologic DMARD, % | 69.2 | 71.2 | 58.3 |
| Glucocorticoids, % | 51.3 | 47.0 | 75.0 |
CQR: Compliance-Questionnaire-Rheumatology; DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; SSZ: sulfasalazine; LEF: leflunomide; HCQ: hydroxychloroquine; AZA: azathioprine.